Lakeshore Biopharma (LSB) Competitors $1.32 -0.18 (-12.07%) Closing price 04/17/2025 03:58 PM EasternExtended Trading$1.25 -0.06 (-4.85%) As of 04/17/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. RENB, ANRO, CABA, ACRV, VIRI, ZIVO, MGX, PYXS, DTIL, and IKNAShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include Renovaro (RENB), Alto Neuroscience (ANRO), Cabaletta Bio (CABA), Acrivon Therapeutics (ACRV), Virios Therapeutics (VIRI), ZIVO Bioscience (ZIVO), Metagenomi (MGX), Pyxis Oncology (PYXS), Precision BioSciences (DTIL), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. Renovaro Alto Neuroscience Cabaletta Bio Acrivon Therapeutics Virios Therapeutics ZIVO Bioscience Metagenomi Pyxis Oncology Precision BioSciences Ikena Oncology Lakeshore Biopharma (NASDAQ:LSB) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability. Do institutionals & insiders believe in LSB or RENB? 52.6% of Lakeshore Biopharma shares are owned by institutional investors. Comparatively, 71.4% of Renovaro shares are owned by institutional investors. 21.7% of Renovaro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in LSB or RENB? Lakeshore Biopharma and Renovaro both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformLakeshore BiopharmaN/AN/ARenovaroN/AN/A Which has more volatility and risk, LSB or RENB? Lakeshore Biopharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Does the media refer more to LSB or RENB? In the previous week, Lakeshore Biopharma had 1 more articles in the media than Renovaro. MarketBeat recorded 2 mentions for Lakeshore Biopharma and 1 mentions for Renovaro. Renovaro's average media sentiment score of 0.00 beat Lakeshore Biopharma's score of -0.50 indicating that Renovaro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakeshore Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Renovaro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LSB or RENB more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets Lakeshore BiopharmaN/A N/A N/A Renovaro N/A -61.84%-48.07% Which has stronger earnings and valuation, LSB or RENB? Lakeshore Biopharma has higher revenue and earnings than Renovaro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeshore Biopharma$672.27M0.02-$61.09MN/AN/ARenovaroN/AN/A-$80.65M-$0.93-0.38 SummaryLakeshore Biopharma beats Renovaro on 5 of the 9 factors compared between the two stocks. Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.28M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E RatioN/A6.9521.9417.82Price / Sales0.02231.01380.9497.68Price / CashN/A65.6738.2634.64Price / Book0.155.936.453.98Net Income-$61.09M$143.22M$3.22B$247.81M7 Day Performance-19.08%4.28%5.85%3.19%1 Month Performance-35.66%-13.11%-9.55%-7.70%1 Year PerformanceN/A-8.51%11.83%1.49% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore Biopharma0.5046 of 5 stars$1.32-12.1%N/AN/A$12.83M$672.27M0.00773Short Interest ↑Gap UpRENBRenovaro0.3348 of 5 stars$0.37+3.8%N/A-83.8%$59.06MN/A-0.4020ANROAlto Neuroscience1.7108 of 5 stars$2.18+4.8%$15.40+606.4%-82.7%$59.02MN/A-0.86N/AGap UpCABACabaletta Bio1.9138 of 5 stars$1.14-2.1%$21.00+1,742.1%-91.8%$57.85MN/A-0.5350ACRVAcrivon Therapeutics1.7154 of 5 stars$1.84+22.6%$23.17+1,159.5%-80.7%$57.66MN/A-0.6858Short Interest ↑High Trading VolumeVIRIVirios TherapeuticsN/A$2.99+1.7%$3.00+0.3%+880.5%$57.58MN/A-11.075News CoverageGap UpZIVOZIVO BioscienceN/A$14.99-0.1%N/A+100.0%$56.83M$15,850.00-3.0710MGXMetagenomi2.0286 of 5 stars$1.51-0.7%$13.00+760.9%-77.9%$56.45M$52.30M-0.58236Positive NewsPYXSPyxis Oncology1.2842 of 5 stars$0.90-1.4%$9.20+919.8%-76.8%$55.56M$16.15M-0.8860News CoverageDTILPrecision BioSciences3.5345 of 5 stars$5.30+18.8%$37.67+610.7%-48.5%$55.56M$68.70M88.35200Short Interest ↑High Trading VolumeIKNAIkena Oncology3.1382 of 5 stars$1.14-2.6%$3.00+163.2%-16.5%$55.01M$659,000.00-0.9370Short Interest ↓News CoveragePositive News Related Companies and Tools Related Companies Renovaro Competitors Alto Neuroscience Competitors Cabaletta Bio Competitors Acrivon Therapeutics Competitors Virios Therapeutics Competitors ZIVO Bioscience Competitors Metagenomi Competitors Pyxis Oncology Competitors Precision BioSciences Competitors Ikena Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LSB Stock Free LSB Stock Alerts